Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Sanofi
  6. Summary
    SNY   US80105N1054

SANOFI

(SNY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
48.28(c) 48.01(c) 48.19(c) 48.38(c) 47.89 Last
1 207 123 2 182 462 1 057 719 7 606 523 1 983 005 Volume
+0.17% -0.56% +0.37% +0.39% -1.01% Change
More quotes
Estimated financial data (e)
Sales 2021 37 415 M 43 873 M 43 873 M
Net income 2021 6 046 M 7 089 M 7 089 M
Net Debt 2021 7 878 M 9 238 M 9 238 M
P/E ratio 2021 17,2x
Yield 2021 4,01%
Sales 2022 39 559 M 46 387 M 46 387 M
Net income 2022 7 137 M 8 369 M 8 369 M
Net Debt 2022 4 042 M 4 740 M 4 740 M
P/E ratio 2022 14,7x
Yield 2022 4,22%
Capitalization 103 B 121 B 121 B
EV / Sales 2021 2,96x
EV / Sales 2022 2,70x
Nbr of Employees 99 412
Free-Float 88,4%
More Financials
Company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular,... 
Sector
Pharmaceuticals
Calendar
09/22 | 05:00amPresentation
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SANOFI
08:32aSANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy fi..
AQ
06:45aPRESS RELEASE : Pfizer and BioNTech Announce -3-
DJ
04:24aSANOFI : Regeneron, Sanofi Say Lung Cancer Drug Libtayo Improves Overall Patient..
MT
12:37aSANOFI : Regeneron's Libtayo Combo Extends Lung Cancer Patients' Lives In Phase ..
MT
09/19SANOFI : ESMO late-breaking data show Libtayo« (cemiplimab) and chemotherapy fir..
AQ
09/18PRESS RELEASE : FDA Advisory Committee Votes -3-
DJ
09/16VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
DJ
09/16PRESS RELEASE : HMNC Brain Health Initiates Pioneering Precision Therapy Program..
DJ
09/15TRANSLATE BIO : LifeSci Index Partners
AQ
09/14TRANSLATE BIO : Sanofi Completes Translate Bio Buyout
MT
09/14SANOFI : Closes On Acquisition Of Translate Bio
MT
09/14SANOFI : completes acquisition of Translate Bio, accelerating the application of..
PU
09/14SANOFI : completes acquisition of Translate Bio, accelerating the application of..
AQ
09/13VALNEVA : stock slumps after Britain ends COVID vaccine deal
RE
09/13NH TherAguix annonce l'approbation de son -2-
DJ
More news
News in other languages on SANOFI
12:18pCAC40 : limite un peu la casse à -1,75% mais 5MdsE échangés
12:13pCAC40 : limite un peu la casse à -1,75% mais 5MdsE échangés
10:52aCAC40 : réduit sa perte à -2%, W-Street ne cède que -1,5%
09:30aCAC40 : l'échéance octobre débute sur une vague de 'risk off'
06:45aGlobeNewswire/Pfizer und BioNTech geben positive -4-
More news
Analyst Recommendations on SANOFI
More recommendations
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SNY | US80105N1054 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 82,01 €
Average target price 104,66 €
Spread / Average Target 27,6%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI-0.43%120 158
JOHNSON & JOHNSON4.09%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY37.19%208 604